This platform is enabling rapid identification of neoantigens, tumor-specific antigens resulting from somatic DNA alterations, expressed by individual patients that are potentially more clinically viable vaccine targets.17 Although whole-exome and mRNA sequencing can rapidly identify potential neoantigens in individual tumors, defining the neoantigens that can be generated by the tumor cell MHC-I processing machinery, can bind to the individual’s HLA and be presented to the cognate CD8+T cell in an immunogenic fashion, therefore, clinically relevant, remains a challenge. This evidence concerns the gene CD8A and neoplasm.